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ABSTRACT 
There is a clinical need for non-invasive biomarkers of tumor hypoxia for prognostic and 
predictive studies, radiotherapy planning and therapy monitoring. Oxygen enhanced 
MRI (OE-MRI) is an emerging imaging technique for quantifying the spatial distribution 
and extent of tumor oxygen delivery in vivo. In OE-MRI, the longitudinal relaxation rate 
of protons (∆R1) changes in proportion to the concentration of molecular oxygen 
dissolved in plasma or interstitial tissue fluid. Therefore, well-oxygenated tissues show 
positive ∆R1. We hypothesized that the fraction of tumor tissue refractory to oxygen 
challenge (lack of positive ∆R1, termed “Oxy-R fraction”) would be a robust biomarker of 
hypoxia in models with varying vascular and hypoxic features. Here we demonstrate 
that OE-MRI signals are accurate, precise and sensitive to changes in tumor pO2 in 
highly vascular 786-0 renal cancer xenografts. Furthermore, we show that Oxy-R 
fraction can quantify the hypoxic fraction in multiple models with differing hypoxic and 
vascular phenotypes, when used in combination with measurements of tumor 
perfusion. Finally, Oxy-R fraction can detect dynamic changes in hypoxia induced by 
the vasomodulator agent hydralazine. In contrast, more conventional biomarkers of 
hypoxia (derived from blood oxygenation-level dependent MRI and dynamic contrast-
enhanced MRI) did not relate to tumor hypoxia consistently. Our results show that the 
Oxy-R fraction accurately quantifies tumor hypoxia non-invasively and is immediately 
translatable to the clinic.  
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INTRODUCTION  
 
Hypoxia is a common feature of most solid malignancies, resulting from an imbalance 
between oxygen delivery and consumption (1). Tumor hypoxia is associated with the 
activation of angiogenesis and with metastatic potential (2). Consequently, tumor 
hypoxia is an important negative prognostic factor (3-5). Tumor hypoxia also mediates 
resistance to radiotherapy and to some chemotherapy agents and is an independent 
predictor of treatment failure. Strategies to counteract tumor hypoxia using either 
radiosensitizers or hypoxia-activated cytotoxic agents are currently being evaluated (6).  
 
A non-invasive imaging biomarker that identifies the presence of hypoxia and measures 
its extent and spatial distribution within a tumor would help facilitate personalized 
medicine. However, no such tool is currently available. Proton (1H) MRI is used 
routinely in clinical medicine, making it an attractive non-invasive modality for 
measuring oxygen delivery and hypoxia in tumors. Current 1H MRI methods of imaging 
hypoxia have focused on either dynamic contrast enhanced MRI (DCE-MRI) or R2*-
based intrinsic susceptibility imaging, also referred to as blood oxygenation level 
dependent (BOLD) imaging (7).  
 
In DCE-MRI, administration of a gadolinium-based contrast agent allows estimation of 
blood vessel flow and permeability, providing an indirect measurement of oxygen 
delivery and necrosis (8). In BOLD imaging, paramagnetic deoxyhemoglobin molecules 
in erythrocytes create magnetic susceptibility perturbations around blood vessels, 
which increase the local transverse MRI relaxation rate (R2*; units ms-1). The value of 
tumor R2* decreases when blood oxygen saturation increases following inhalation of 
hyperoxic gas (9). Unfortunately, both DCE-MRI and BOLD imaging have significant 
limitations which have hindered implementation as clinical biomarkers of hypoxia (10). 
Neither measure hypoxia directly. Further, BOLD measurements are affected by 
presence of hemorrhage, by change in vessel geometry and by artifact in air/soft tissue 
interfaces, such as in the lungs and bowel (7).  
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Oxygen enhanced MRI (OE-MRI) is a distinct 1H MRI method for quantifying tumor 
oxygen delivery. Here, the MRI longitudinal relaxation rate (R1; units s-1) is sensitive to 
changes in the level of molecular oxygen (O2) dissolved in blood plasma or interstitial 
tissue fluid (11, 12). When hyperoxic gas is inhaled, excess oxygen is carried in the 
blood plasma in tissues with adequate perfusion. Since well oxygenated tissue has 
near complete saturation of hemoglobin molecules (13), the excess delivered oxygen 
remains dissolved in blood plasma and interstitial tissue fluid, where it increases the R1 
value (Figure 1a). The change in R1 (∆R1) observed is theoretically proportional to 
magnitude of change in dissolved O2 concentration for a given voxel (11) (Figure 1b). 
Several previous studies have reported positive average values of ∆R1 following 
oxygen inhalation in preclinical models of cancer (14-22) and in human tumors (20, 23-
25). Importantly, while both oxygen relaxivity, baseline R1 and signal-to-noise ratios 
show some variation with field strength, the technique is feasible on both preclinical and 
clinical MRI platforms (22, 26).   
 
Measuring positive ∆R1 in OE-MRI quantifies and maps oxygen delivery by identifying 
tissue with fully saturated hemoglobin, but does not directly identify tissue hypoxia per 
se. Tumor sub-regions refractory to oxygen challenge are considered to have low 
hemoglobin oxygen saturation and so excess delivered O2 molecules bind preferentially 
to hemoglobin molecules but do not significantly alter plasma pO2 (10) (Figure 1c). 
Several preclinical OE-MRI studies have reported that some tumor sub-regions are 
refractory to hyperoxic gas challenge since they had no positive ∆R1 change (14, 19-
21). If these regions are perfused yet lacking in oxygen enhancement then OE-MRI 
should identify regions of tumor hypoxia (Figure 1d). In this study, we tested the 
hypothesis that measuring the fraction of each tumor refractory to oxygen challenge – 
determined by having absent positive ∆R1 (hereafter termed “Oxy-R fraction”) – would 
enable the identification, quantification and mapping of tumor hypoxia with MRI in vivo. 
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MATERIALS AND METHODS  
 
Phantom validation of R1 measurement 
In vitro validation experiments were performed on the same 7T system as used for the 
in vivo studies. The phantom consisted of four 5mm NMR tubes (Sigma- Aldrich, UK) 
with solutions of gadopentetate dimeglumine (Magnevist; Schering, Berlin, Germany) 
serially diluted in water to yield final concentrations of 0.01, 0.05, 0.07 and 0.09mM 
gadolinium and an expected range of T1 between 1400-2500ms based on the relaxivity 
of Magnevist at 7T at 37°C (27). NMR tubes were placed inside a plastic container filled 
with dental paste to reduce susceptibility effects and to ensure efficient heat transfer for 
constant temperature. Three repeated measurements of R1 were measured for each 
tube on three separate days.  
 
Tumor implantation 
All experiments were performed in compliance with licenses issued under the UK 
Animals (Scientific Procedures) Act 1986 and following local ethical review. Studies 
were compliant with the United Kingdom National Cancer Research Institute guidelines 
for animal welfare in cancer research (28) and with the ARRIVE guidelines (29).  
 
Three cell lines exhibiting differing vascular and hypoxic phenotypes in vivo were used. 
Parental 786-0 renal carcinoma cells (ATCC, LCG Standards, Teddington, UK; 
purchased 2011; 786-0-par), and cells established from a sunitinib refractory 
subcutaneous 786-0 xenograft (786-0-R) (30), were cultured in RPMI supplemented 
with 10% (v/v) fetal calf serum (Gibco, Life Technologies, Paisley, UK). Tumors were 
propagated by injecting 3x106 cells in 100µl of sterile PBS into the flanks of 8 week old 
female C.B17-scid mice under isoflurane anesthesia. SW-620 colorectal carcinoma 
cells (ATCC; lot #8924081, purchased 2005) were cultured in DMEM supplemented 
with 10% fetal calf serum. Tumors were propagated by injecting 5 x106 cells in 100µl of 
sterile PBS into the flanks of 8 week old female athymic NCr-Foxn1nu mice. Immediately 
prior to in vivo implantation, all cells tested negative for mycoplasma infection and the 
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number of short tandem repeats (STRs) present at 7-10 loci were assessed by PCR to 
provide STR profiles, from which cell line authenticity was confirmed. 
 
Tumor size was monitored using callipers and the formula for ellipsoid volume, (π/6) 
× L × W × D, where L, W and D are the largest orthogonal dimensions of the ellipsoid. 
Tumors were typically used for experimentation at a volume of approximately 400mm3. 
 
Measurement of tissue pO2 
The fiber optic oxygen sensing device OxyLiteTM (Oxford Optronix, Oxford, UK) (31) 
was used to measure tumor partial pressure of oxygen (pO2; units mm Hg). A heat mat 
maintained core body temperature and gas delivery was at 2l/min via a nosepiece. Two 
dual pO2 and temperature probes were positioned within the tumor tissue. Animals 
initially breathed medical air, followed by 100% oxygen to mimic the gas changes 
induced during the MRI experiments. Data acquisition and averaging were performed 
using Chart version 5 (AD Instruments, Castle Hill, Australia). Tissue pO2 data were 
collected the day after corresponding MRI data. 
 
MRI data acquisition 
Anesthesia was induced with a 10 ml/kg intraperitoneal injection of fentanyl citrate 
(0.315 mg/ml) plus fluanisone (10mg/ml) (Hypnorm; Janssen Pharmaceutical Ltd, High 
Wycombe, UK), midazolam (5mg/ml) (Hypnovel; Roche, Welwyn Garden City, UK) and 
sterile water (at 1:1:2 ratio) (16). Mice were positioned in a 3cm birdcage coil on a 
custom built platform to isolate the tumor, which was surrounded by dental paste (3M; 
Bracknell, UK) to minimize motion and susceptibility artifacts. Gas delivery (medical air 
or 100% oxygen) was continuous at 2l/min through a nose piece. Warm air maintained 
animal core temperature at 37°C. Lateral tail vein cannulation was performed with a 
heparinised 27G butterfly catheter (Venisystems, Hospira, Royal Leamington Spa, UK) 
to enable the remote intravenous administration of gadolinium contrast agent in DCE-
MRI studies or when vasomodulator was administered.  
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All MRI data were acquired on a 7T horizontal bore microimaging system (Bruker 
Instruments, Ettlingen, Germany). Localization was performed using a multi-slice 
turboRARE T2-weighted sequence and was followed by shimming over the tumor (32). 
All sequences were acquired using 30mm x 30mm FOV (128 x 128 matrix; in plane 
resolution 0.234mm) for a single 1 mm thick slice. Experimental protocols are detailed 
in Supplementary Figure S1. Sequences used were: 
 
OE-MRI: Inversion recovery (IR) True-FISP images were used to calculate R1 (TR 
2.4ms, scan TR 10s, 48 inversion times spaced 38.8ms apart with initial inversion time 
of 106.2ms; TE 1.2ms; α 60°). High signal-to-noise (SNR) images were used to obtain 
highly accurate R1; these required 8 signal averages and took 10min 40s to perform. 
Dynamic images were used to quantify the temporal onset of R1 changes induced by 
switching between air and 100% oxygen. The dynamic images required 2 signal 
averages and took 2min 40s to perform.  
 
BOLD: Multiple gradient echo (MGE) images were used to calculate R2* (TR 200ms; 8 
echo times, TE 6.2 to 28.2ms with 3.1ms echo spacing; 8 signal averages); duration 
3min 25s. 
 
DCE-MRI: Data were collected using a modified True-FISP sequence (TR 2.4ms, scan 
TR  10s, 8 inversion times spaced 155ms apart, initial inversion time 108ms, TE 1.2ms; 
α 60°; one signal average, temporal resolution 20s). After five baseline measurements, 
0.1mmol/kg bolus of the gadolinium-based contrast agent Magnevist (2ml/kg 50mM 
solution) was injected intravenously at 2ml/min using a power injector; duration 10mins. 
 
MRI analysis 
Regions of interest (ROIs) were drawn around the tumor on the T2-weighted images by 
an experienced operator (YJ). ROI were transferred to all OE-MRI, BOLD and DCE-
MRI data. Voxel-wise and median values of R1 and R2* were calculated for each map 
using a Bayesian maximum a posteriori approach, with in-house software.  
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For OE-MRI the voxel wise ∆R1 was calculated, where ∆R1 = R1 (O2) – R1 (air). The 
initial R1 (air) was derived from the average of the first two high SNR R1 maps. The R1 
(O2) was derived from the high SNR R1 map acquired during oxygen breathing. Oxygen 
enhancement was measured as 2 x tumor baseline R1 x cohort CoV. Voxels were then 
classified as enhancing (termed “Oxy-E) or refractory (termed “Oxy-R”) to oxygen 
challenge. Voxel-wise BOLD ∆R2* was calculated, where ∆R2* = R2* (O2) – R2* (air).  
 
Where DCE-MRI was performed, the initial area under the contrast agent concentration 
curve from 0 to 60 seconds (IAUC60) was calculated (16) and voxels were classified as 
enhancing when IAUC60 >0. Where both OE-MRI and DCE-MRI were acquired, data 
were combined to distinguish three tumor sub-regions from one another: (1) perfused 
Oxy-E voxels; (2) perfused Oxy-R voxels; and (3) non-perfused voxels.   
 
Hydralazine challenge 
Hydralazine acts directly on vascular smooth muscle in vessels of normal tissues, 
causing vasodilation and reduced mean arterial blood pressure. Tumor blood vessels 
lacking smooth muscle do not dilate in response to hydralazine. Hence, blood is 
redistributed away from the tumor, reducing blood flow and increasing hypoxia within 
30 minutes (33-36). Hydralazine challenge has, therefore, been used as a tool to 
manipulate acute hypoxia.  
 
An initial air–to–oxygen gas challenge was performed. Then gas delivery was switched 
back to air breathing and intravenous injection of either 5mg/kg hydralazine 
hydrochloride (Sigma-Aldrich Co., Dorset, UK) or saline was performed. Finally, a 
second air–to–oxygen gas challenge was performed. Spatial differences between the 
∆R1 defined Oxy-E and Oxy-R voxels on the two air–to–oxygen challenges were 
assessed by mismatch mapping. Formal randomisation was not employed, rather 
during each day’s scanning mice were prospectively assigned with intent to balance 
treatment groups according to tumour size. 
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Immunofluorescence analysis 
Intraperitoneal injection of 60mg/kg pimonidazole (Hypoxyprobe, Burlington, MA) was 
performed 55 minutes before 100% O2 inhalation began to allow for maximal 
bioreduction of the agent in hypoxic tumor regions. 15mg/kg Hoechst 33342 (Sigma-
Aldrich Co., Dorset, UK) was administered intravenously one minute prior to rapid 
tumor excision. Tumors were excised whole and bisected along the imaging plane so 
that the cut surface approximated to the MRI region of interest. Half the tumor was 
snap frozen and half was formalin fixed and paraffin embedded.  
 
Frozen tissue sections (5µm) were obtained from snap frozen tumor material and 
scanned using fluorescent microscopy on a Panoramic 250 Flash system (3DHistech, 
Budapest, Hungary) to determine the number of Hoechst-stained (perfused) vessels 
(excitation 350nm/emission 480nm). Pimonidazole binding was determined in the same 
sections using Hypoxyprobe-1 (Hypoxyprobe, Burlington, MA), a mouse-monoclonal, 
followed by rabbit anti-mouse-fluorescein isothiocyanate (FITC) conjugated secondary 
antibody (excitation 488nm/emission 525nm). Paraffin embedded sections (5µm) were 
obtained from tumor tissue dehydrated after fixation in 10% phosphate-buffered 
formalin. Sections were stained with hematoxylin and eosin (H&E). Data was analyzed 
using ImageJ software (NIH, Bethesda, MD). The perfused vessel area, hypoxic 
fraction and percentage necrosis were calculated, as described elsewhere (37). 
 
Statistical analysis 
IBM SPSS Statistics v.22 (Armonk, NY) was used for all statistical analysis. In all 
cases, p values of <0.05 were considered significant. Comparison of median values of 
R1 during medical air only breathing and during oxygen challenge experiments were 
evaluated using a one way analysis of variance (ANOVA) with a post hoc Bonferroni 
correction for multiple comparisons.  
 
Data comparing median values of R1, R2* and IAUC60 and fractions of Oxy-E or Oxy-R 
between different tumor cohorts (786-0-R, 786-0-par or SW620) were evaluated with 
independent t-tests corrected for multiple comparisons. Data for different cohorts were 
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assumed to be distributed normally and have unequal variance. Correlations between 
MRI and pathology were assessed by the non-parametric Spearman’s rho. Formal 
sample size calculations were not performed.  
Research. 
on December 15, 2015. © 2015 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 9, 2015; DOI: 10.1158/0008-5472.CAN-15-2062 
12 
 
RESULTS  
 
OE-MRI signals are accurate, precise, stable and sensitive to pO2 change  
We sought to demonstrate OE-MRI signal precision, stability and sensitivity to altered 
oxygen tension, because these factors have not been well documented. Since OE-MRI 
signal changes are based on the longitudinal relaxation rate, R1, we compared the 
expected R1 against the measured R1 in an in vitro phantom. These data showed that 
our R1 measurement technique is accurate (Supplementary Figure S2).  
 
To test measurement precision and stability in vivo, we then performed an experiment 
in four mice implanted with subcutaneous 786-0-R tumors (786-0-R is a fast-growing 
subline of the 786-0 renal cancer cell line). Mice initially breathed medical air for 40 
minutes. This was followed by 100% oxygen challenge for 20 minutes. Finally the mice 
breathed medical air again for 25 minutes. Multiple R1 maps were acquired 
(Supplementary Figure S1a). The within-scan co-efficient of variation (CoV) of baseline 
voxel-wise R1 was 0.41% in vivo, indicating high measurement precision. No 
appreciable difference was observed in the spatial mapping of tumor R1 during air 
breathing (see time points 1-7 in Figure 2a). No significant change was seen in tumor 
R1 in the four mice (Figure 2b), indicating signal stability while breathing air. 
 
Challenge with 100% oxygen was then performed in the same mice, to increase tumor 
pO2. All four tumors showed rapid, heterogeneous and significant increase in median 
R1 following oxygen challenge. These changes were clearly visible in the first map after 
2min 40s of oxygen breathing and persisted for the duration of the oxygen challenge 
(p<0.008 for all time points 8-12 compared with air breathing) showing consistent 
spatial arrangement (Figure 2a-b). Across all four tumors, 89.3% of voxels were oxygen 
enhancing (Oxy-E) and 10.7% of voxels were oxygen refractory (Oxy-R). Sample traces 
of ∆R1 change are shown for Oxy-E and Oxy-R voxels (Supplementary Figure S3). 
OxyLiteTM measurement in the same tumors showed pO2 increase (beyond the limit of 
detection of the OxyLiteTM equipment, namely at 100mmHg) in 7 out of 8 measured 
regions over the same time frame (sample trace in Figure 2c). The OxyLiteTM data 
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provides independent evidence that OE-MRI detects real time increases in the oxygen 
concentration in tumor interstitial tissue fluid. BOLD MRI, performed in the same mice, 
revealed a significant reduction in R2* during oxygen challenge (mean reduction 39.8 
ms-1; SE 11.7 ms-1; p=0.043), consistent with previous studies (38).  
 
Tumors showed rapid reversal of R1 changes when oxygen challenge ended and air 
breathing was resumed (see time points 13-17 in Figure 2a). There was no significant 
difference between baseline and end-of-study mean R1 values for the cohort. OxyLiteTM 
measurement showed pO2 return to pre-challenge levels over a period of 2 to 6 minutes 
mirroring ∆R1 change. Collectively these data confirm that R1 measurements used for 
this study are accurate, precise, stable in the absence of perturbation and sensitive to 
change in tumour pO2.  
 
Oxy-R fraction detects differential levels of hypoxia in an isogenic system 
We investigated whether Oxy-R fraction (the fraction of each tumor refractory to oxygen 
challenge) could detect different levels of hypoxia in cancer models. We measured the 
Oxy-R fraction in two isogenic cell lines: the slow growing parental 786-0 cell line (786-
0-par), which took 206.3 days ± 66.2 SD to reach a tumor volume of ~400 mm3 (n = 8 
mice), and the much faster growing 786-0 subline (786-0-R), which only took only 32.1 
days ± 6.9 SD to reach the same tumor volume (n = 9 mice). From these mice we 
acquired OE-MRI, ∆R2* and DCE-MRI data along with histopathological analysis of 
pimonidazole adduct formation (for hypoxia) and Hoechst 33342 uptake (for perfusion) 
(Supplementary Figure S1b). 
 
Staining for pimonidazole adduct formation showed a significantly higher hypoxic 
fraction in 786-0-R tumors compared to the 786-0-par tumors (p=0.008) (Figure 3a). 
This finding was mirrored by the Oxy-R fraction being significantly higher in the 786-0-R 
xenografts compared with the 786-0-par xenografts (p=0.047) (Figure 3b). In 
distinction, there was no significant difference in the median values of ∆R1, IAUC60 or 
∆R2* between the 786-0-R and 786-0-par xenografts (Figure 3c-e). No significance 
difference was seen in the perfused vessel area measured by Hoechst 33342 staining 
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(data not shown). These data confirm that Oxy-R fraction is sensitive to differential 
levels of hypoxia but that median values of ∆R1, IAUC60 and ∆R2* were insensitive to 
this difference.  
   
Perfused Oxy-R quantifies hypoxic fraction  
We sought to test if Oxy-R fraction could estimate tumor hypoxic fraction in two tumor 
models originating from different cell lines. In particular, we wanted to test if the 
presence of avascular or necrotic tumor tissue – which does not receive any delivery of 
oxygen gas in the blood plasma – would confound the relationship between Oxy-R and 
hypoxia. Therefore we analyzed data from the perfused portion of each tumor.   
 
To do this, we first used the 786-0-R data already collected. We examined the within 
cohort correlation between Oxy-R fraction and the pimonidazole adduct formation 
based measurement of hypoxic fraction. This model is known to be highly vascularized. 
Further, there was a wide dynamic range of hypoxia in this model. We then performed 
an equivalent experiment using SW620 tumors. This model was chosen because these 
tumors are relatively poorly vascularized (39).  
 
Anticipated differences in the perfusion status of the two models were confirmed; 786-
0-R xenografts had significantly greater perfused tumor area compared with SW620 
xenografts, measured by DCE-MRI (p=0.011) (Table 1) and by Hoechst 33342 
(p=0.004). Pathology analysis showed that perfused vessel area measured by Hoechst 
33342 (Supplementary Figure S4a-b) correlated with perfused Oxy-E fraction (those 
voxels showing positive enhancement with both oxygen and gadolinium) and that non-
perfused fraction correlated with necrosis on H&E in both models (Supplementary 
Figure S4c-d). 
 
Oxy-R fraction correlated strongly with pathological hypoxic fraction in 786-0-R tumours 
(rho 0.810, p=0.028) (Figure 4a), irrespective of whether the entire tumor was analyzed 
or if analysis was restricted to gadolinium-enhancing tumor only (perfused Oxy-R 
fraction). In SW620 tumours the Oxy-R fraction did not correlate with hypoxic fraction 
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(measured by pimonidazole adduct formation). However, as anticipated the perfused 
Oxy-R fraction and hypoxic fraction (measured by pimonidazole adduct formation) 
correlated strongly (rho 0.929, p=0.002) (Figure 4b). In both models, visual inspection 
revealed that perfused Oxy-R voxels were located at an interface between the 
peripheral perfused Oxy-E voxels and the centrally located non-perfused voxels. 
Collectively, these data provide evidence that Oxy-R fraction can quantify hypoxic 
fraction accurately, but requires perfusion data in poorly vascularized tumors.   
 
Oxy-R fraction is sensitive to dynamic change in hypoxia 
In order to provide evidence that Oxy-R fraction can detect reduced oxygen delivery to 
tumors, we administered the vasomodulator hydralazine to a cohort of mice bearing 
786-0-R xenografts (n=4 mice) and compared with control mice receiving saline (n=6 
mice). We performed an air–to–oxygen challenge before and after the administration of 
hydralazine or control (Supplementary Figure S1c). In the initial air–to–oxygen 
challenge, overall ∆R1 changes were positive, as expected in all ten mice (Figure 5a).  
 
Importantly, the second air–to–oxygen challenge was initiated 15 minutes after 
administration of hydralazine or saline. The magnitude of ∆R1 was reduced significantly 
in mice receiving hydralazine, relative to control (Figure 5a) (p<0.01). This difference in 
hydralazine-treated tumors was driven by the Oxy-R fraction increasing significantly 
from 17.3% to 30.5% (p=0.045) (Figure 5b).  
 
To further understand these changes, we used ‘mismatch mapping’ to identify tumor 
sub-regions that changed oxygen enhancement status. In control tumors, the majority 
of voxels remained consistently either Oxy-E or Oxy-R. The number of voxels changing 
from Oxy-E to Oxy-R or vice versa was equal for both directions of change and was 
small (Figure 5c). In hydralazine treated tumors, substantially more voxels turned from 
Oxy-E to Oxy-R than vice versa. Some of these newly Oxy-R tumor sub-regions were 
immediately adjacent to established Oxy-R regions, but other new areas of Oxy-R were 
detected at spatially distant sub-regions (Figure 5d). These data confirm that OE-MRI 
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can detect dynamic change in tumor hypoxia. Further, tumor regions with appearing or 
resolving hypoxia can be mapped using this technique.  
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DISCUSSION 
 
Hypoxia is an important prognostic factor for solid tumors and mediates resistance to 
radiotherapy and to some chemotherapy agents. Non-invasive clinical imaging has 
potential to improve patient care by producing biomarkers that alter clinical decision 
making (40, 41). In the case of hypoxia, a clinically translational imaging biomarker has 
potential to be prognostic and/or predictive (identifying presence of hypoxia and 
quantifying hypoxic fraction/volume prior to therapy), to assist treatment planning 
(mapping targets for radiation boost or adaptive therapy) (42), or to monitor therapy 
induced changes in tumor hypoxia, for example following radiosensitisation or hypoxia 
activated cytotoxic therapy (10, 43). 
 
To date, clinical strategies to image tumor hypoxia have been dominated by positron 
emission tomography (PET) methods (7). Several investigational PET tracers have 
been evaluated, each with slightly different underlying relationship to tissue oxygen 
tension (44, 45). However, at present no imaging method identifies and maps the 
extent of tumor hypoxia that is validated, cost-effective, widely available and used for 
patient benefit (7).  
 
OE-MRI is an emerging technique that detects the presence of excess dissolved O2 
molecules in plasma and tissue fluid. Most OE-MRI studies in cancer have been small 
cohort based studies, and without corresponding pathology or intervention, tending to 
report changes in median signal intensity or median ∆R1. In well oxygenated tumor 
tissue, oxygen-induced ∆R1 signals are positive, similar to signal changes observed in 
healthy tissues (46, 47). Advances in OE-MRI have focused largely around providing 
dual ∆R1 and ∆R2* acquisitions (25) or in enhancing the magnitude of oxygen-induced 
∆R1, for example by developing methods sensitive to tumor lipid signals (17). 
 
In this study, we adopted a different approach. We focused on the fact that tumors are 
biologically heterogeneous, composed of sub-regions with distinct pathophysiology (48, 
49). Previous OE-MRI studies have suggested that some tumor sub-regions are 
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refractory to the positive ∆R1 induced by oxygen-challenge (14, 20). We built on this 
observation by partitioning the OE-MRI signal into regions with enhancing (Oxy-E) or 
refractory (Oxy-R) signatures. We conducted a series of experiments to test the 
hypothesis that Oxy-R fraction tumor can identify, quantify and map tumor hypoxia.   
 
We first used the renal carcinoma model 786-0-R (rapid growing, vascular tumors with 
anticipated large oxygen-induced ∆R1) to develop a protocol that was not only stable 
while breathing medical air, but also sensitive to oxygen-induced signals. This is the 
first study to provide detailed evidence of measurement stability and sensitivity for 
serial R1 mapping in OE-MRI. The temporal evolution of oxygen-enhanced positive ∆R1 
occurred within 3 minutes and was spatially stable. The OE-MRI data mirrored 
OxyLiteTM measurement of pO2 changes, concurring with data from a previous study 
where rapid increases in ∆R1 were observed following gas challenge (15) and with data 
comparing OE-MRI signal changes with 19F oximetry (19).  
 
Next, we demonstrated that Oxy-R fraction could distinguish differences in hypoxic 
fraction within tumors derived from two isogenic cell lines: parental 786-0 cells and 786-
0-R cells. Here, the relatively rapid growing 786-0-R tumors had significantly more 
hypoxia than the slow growing 786-0-par tumors. Crucially, Oxy-R fraction distinguished 
between cell lines, mirroring differences observed in values of hypoxic fraction 
quantified through pimonidazole staining.  
 
We then tested if Oxy-R fraction could estimate hypoxic fraction. We chose the 786-0-R 
and SW620 models because of their differing perfusion characteristics. Significant 
correlation was seen between Oxy-R fraction and hypoxic fraction (defined on 
pimonidazole adduct formation) in the relatively well perfused 786-0-R xenografts. This 
association was not replicated in the poorly perfused SW620 xenografts because many 
Oxy-R voxels had negligible perfusion, so received insufficient oxygen gas to alter 
voxel R1. Having accounted for these voxels using DCE-MRI, we measured Oxy-R 
fraction in perfused tissue and observed a significant association in the SW620 tumors.  
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We then increased the fraction of tumor hypoxia in a further cohort of 786-0-R tumors 
using the vasomodulator hydralazine. Oxy-R fraction increased two-fold, providing 
direct evidence that OE-MRI can track acute changes in tumor oxygenation. Some 
signal fluctuation was observed in both directions in hydralazine and control tumors. 
This may reflect changes in acute transient hypoxia (50), but further work is required to 
understand these signal changes.     
 
In these experiments, median ∆R1 (the most common biomarker derived from OE-MRI 
data) was unable to distinguish the differing levels of hypoxia between the 786-0 sub-
lines and did not correlate with the degree of hypoxic fraction within the SW620 tumors. 
We also compared the Oxy-R analysis approach with BOLD MRI. Oxygen-induced 
∆R2* did mirror changes in tissue pO2, similar to previous reports (38), but ∆R2* did not 
differ between the 786-0 sub-lines with differing levels of hypoxia, nor did ∆R2* relate to 
degree of hypoxic fraction in 786-0-R or SW620 tumors, suggesting that R2* 
measurements were confounded by other factors, such as vessel flow. These findings 
are consistent with previous reports of inconsistent relationships between ∆R2* and 
pimonidazole-based assay of hypoxic fraction (38). 
 
Our findings are important for at least four reasons. Firstly, these data demonstrate that 
positive ∆R1 changes on OE-MRI imaging are sufficiently precise, stable and strong 
enough to be measured reliably. This enables those portions of tumor refractory to 
positive signal change (i.e. Oxy-R sub-regions) to be identified with confidence. 
Secondly, these data suggest that in OE-MRI, Oxy-R fraction relates more closely to 
tumor hypoxia than median ∆R1. This supports further evaluation of Oxy-R fraction or 
Oxy-R tumor volume as a prognostic and/or predictive biomarker. Thirdly, Oxy-R voxels 
were located in spatially distinct sub-regions suggesting that, if replicated in humans, 
this technique may facilitate the planning of localized boost and adaptive radiotherapy 
delivery strategies. Fourthly, clinical tumors vary in their extent of perfusion and this 
may further change with therapy. Our data suggest that subsequent studies of OE-MRI 
in patients with cancer should evaluate Oxy-R fraction in perfused tumor regions (using 
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a combined analysis with DCE-MRI or an equivalent technique), rather than using OE-
MRI in isolation.  
 
In conclusion, these data provide substantial evidence to validate the measurement of 
Oxy-R fraction to identify, quantify and map tumor hypoxia. Unlike other nuclear 
magnetic resonance techniques such as electron paramagnetic resonance oximetry, 
19F oximetry and Overhauser enhanced MRI – which are either invasive or require use 
of an investigational diagnostic agent, hindering clinical translation (7) – Oxy-R fraction 
can be readily quantified on clinical MRI scanners (24), making the technique suitable 
for rapid clinical translation. 
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TABLE 
Table 1 
Proportions of Oxy-E and Oxy-R tumor (with standard deviation; SD), subdivided by 
voxel perfusion status 
 
 % Oxy-E voxels % Oxy-R voxels 
Perfused Not perfused Perfused Not perfused 
786-O-R 78.2 
(SD18.3) 
7.2 
(SD 5.9) 
13.2 
(SD 12.9) 
1.2 
(SD 1.6) 
Parental 786-O 84.7 
(SD 14.0) 
11.0 
(SD 12.2) 
3.4 
(SD 2.5) 
0.9 
(SD 0.8) 
SW620 51.5 
(SD 13.8) 
25.2 
(SD 14.9) 
15.7 
(SD 6.2) 
7.6 
(SD 4.3) 
 
 
 
FIGURE LEGENDS 
Figure 1 
OE-MRI distinguishes between normoxic and hypoxic tissue. Each box represents 
an imaging voxel which contains erythrocytes (red spheres) in blood vessels (pink 
cylinders); tumor cells (gray ellipse); and surrounding interstitial space (white box).  A. 
In normoxic tissue, hemoglobin molecules in erythrocytes are oxygen saturated and 
form oxyhemoglobin (HbO2) molecules. Dioxygen molecules (O2) are dissolved in the 
plasma. Inhalation of hyperoxic gas markedly increases the amount of dissolved 
plasma O2 but HbO2 concentration is essentially unaltered. B. Increased pO2 in 
interstitial fluid and plasma increases tissue longitudinal relaxation rate (R1), which is 
detected by MRI. C. In hypoxic tissue, hemoglobin molecules are not fully oxygen 
saturated and exist as deoxyhemoglobin (Hb) molecules. Inhalation of hyperoxic gas 
increases the HbO2 to Hb ratio but has negligible effect on plasma O2. D. Since there is 
negligible change in pO2 the R1 remains little changed (straight black line). Since Hb 
has a slightly higher longitudinal relaxivity than HbO2, tissue R1 may even decrease 
(dotted black line).  
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Figure 2  
OE-MRI signals are precise, stable and sensitive to pO2 change. A, R1 maps in one 
786-0-R xenograft tumor while the mouse breathed air (top row), 100% oxygen (middle 
row) and back to air (bottom row). B, R1 measurement was stable in four mice with 786-
0-R xenografts during the initial 45 minutes of air breathing. Symbols: ■ 10m40s IR-
TrueFISP acquisition, ♦ 2m40s acquisition. Rapid and significant changes in median R1 
were induced by 100% oxygen challenge in the same animals and rapid return to 
baseline values was observed once air breathing resumed. Mean of individual tumor 
medians are shown ± 1 s.e.m. C, OE-MRI signal changes mirror the time course of 
change in tumor pO2 as shown in a sample OxyliteTM trace from one xenograft 
(maximum to the detection range was 100mmHg).   
Figure 3  
Oxy-R fraction identifies differential levels of hypoxia. A, 786-0-R xenografts had 
significantly greater pimonidazole adduct derived hypoxic fraction than 786-0-par 
xenografts, mirrored in B, Oxy-R fraction tumor. No difference was seen in C, median 
∆R1, D, median IAUC60 or E, median ∆R2* between the two cell lines. All error bars are 
1 s.e.m., *p<0.05.   
Figure 4  
Perfused Oxy-R fraction measures hypoxic fraction in multiple tumor models. 
Representative OE-MRI and DCE-MRI maps from A, 786-0-R and B, SW620 tumors 
are binarized to show enhancing and non-enhancing voxels. For combined MRI data 
the voxels are color coded as perfused Oxy-E (yellow), perfused Oxy-R (blue) and non-
perfused (gray). Immunofluoresence was performed to map tumor hypoxia by 
pimonidazole adduct formation. In 786-0-R tumors Oxy-R fraction correlated with 
hypoxic fraction (and this relationship was maintained when only perfused voxels were 
assessed). In SW620 tumors, Oxy-R fraction did not correlate significantly with hypoxic 
fraction, which it overestimated. However when analysis is restricted to perfused Oxy-R 
voxels (blue squares) a significant correlation was observed. 
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Figure 5 
Oxy-R detects reduced oxygen delivery induced by hydralazine. A, Time course of 
the ∆R1 in 786-0-R xenografts challenged with 100% oxygen, before and after 
intravenous injection of either saline control or 5mg/kg hydralazine hydrochloride. Mean 
of initial two air breathing R1 values taken as baseline for subsequent ∆R1. All error 
bars are 1 s.e.m. B, Hydralazine-treated tumors showed increase in the Oxy-R fraction 
with the second oxygen challenge, relative to control. Oxy-E (white) and Oxy-R (black) 
voxels are mapped for each oxygen challenge in example control and hydralazine 
treated tumors. C, Mismatch mapping reveals that approximately equal numbers of 
voxels switch from Oxy-R to Oxy-E (red) and from Oxy-E to Oxy-R (green) in the 
control tumor. Most voxels remain either Oxy-E (white) or Oxy-R (black) throughout. D, 
In distinction, Oxy-R fraction increases on the second oxygen challenge with 
hydralazine due to substantially more voxels switching from Oxy-R to Oxy-E (red) than 
from Oxy-E to Oxy-R (green).  
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